NMBS-1 / Nimbus Therap - LARVOL DELTA

A Novel Lipid Microbubble Targeting E-Selectin for Ultrasound Molecular Imaging of Acute Kidney Injury in Rats. (PubMed, Mol Pharm) - "Using freeze-drying methods, three formular nontargeted microbubbles (NMBs-1, NMBs-2, NMBs-3) were prepared, and three corresponding MBE-selectin suspensions (MBE-selectin-1, MBE-selectin-2, MBE-selectin-3) were constructed via maleimide-thiol conjugation chemistry. In conclusion, we successfully prepared a novel MBE-selectin suspension carrying an anti-E-selectin antibody that can be used for intravenous injection and can enhance ultrasound imaging of the kidney as a UCA, particularly in a cisplatin-induced AKI model. Ultrasound molecular imaging of the MBE-selectin suspension may be helpful for evaluating renal microcirculation or injury in AKI diseases."

Journal • Preclinical • Acute Kidney Injury • Inflammation • Nephrology • Oncology • Renal Disease • TNFA

Nimbus Therapeutics Announces $105 Million Private Financing to Advance Pipeline Including Multiple Clinical Programs (Businesswire) - “Nimbus Therapeutics…announced the closing of a $105 million private financing round…the financing will support a first-in-human study of the company’s HPK1 inhibitor candidate in cancer patients with solid tumors, which will begin later this year, and will accelerate preclinical programs against multiple targets in oncology and immunology. The company expects to initiate IND-enabling studies on two novel agents in 2022.”

Financing • IND • New P1 trial • Oncology • Solid Tumor

Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor (Businesswire) - “Nimbus Therapeutics…announced the presentation of data from the company’s HPK1 inhibitor program in a poster at the AACR Annual Meeting held virtually April 10-15, 2021. Newly disclosed data show that Nimbus’ small-molecule HPK1 inhibitor, NMBS-2, demonstrates significant tumor growth inhibition as a single agent and in combination with anti-PD1 in multiple mouse syngeneic tumor models. In combination with anti-PD1, NMBS-2 restored cytokine secretion from exhausted human T cells and induced robust tumor growth inhibition in the CT-26 model…‘We’re rapidly progressing IND-enabling studies of NMBS-2 now with plans to initiate first-in-human studies in the second half of 2021.”

IND • Preclinical • Oncology